viewSilence Therapeutics PLC

Silence Therapeutics Announces Board Change

/**/ link{ color: #0563C1 }visited{ color: #954F72 } .q{size:612.0pt 792.0pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.q{}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";}span.al{font-size:16.0pt;line-height:107%; font-family:"Calibri Light","sans-serif"}p.an{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; margin-left: 0cm; margin-right: 2.5pt; margin-top: 0cm; text-autospace: none}span.ak{font-size:16.0pt;font-family:"Calibri Light","sans-serif"; color:#234060}p.ao{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:2.5pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;line-height:normal;text-autospace:none}p.ap{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:2.5pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal; text-autospace:none}span.ah{color:black}p.aq{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify; text-autospace: none} p.ar{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; margin-left: 5.85pt; margin-right: 0cm; margin-top: 0cm; text-align: justify; text-autospace: none}table.as{width:460.7pt;margin-left:3.4pt;border-collapse:collapse}tr.aa{height:34.15pt}td.ac{width:297.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:34.15pt}p.at{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:5.85pt;margin-bottom:.0001pt;text-align:justify;line-height:normal; text-autospace:none}td.ab{width:120.15pt;padding:0cm 5.4pt 0cm 5.4pt; height:34.15pt}tr.x{height:19.15pt}td.z{width:297.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:19.15pt}td.y{width:120.15pt;padding:0cm 5.4pt 0cm 5.4pt; height:19.15pt}tr.u{height:26.15pt} td.w{width:297.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:26.15pt}td.v{width:120.15pt;padding:0cm 5.4pt 0cm 5.4pt; height:26.15pt}td.t{width:297.35pt;padding:0cm 5.4pt 0cm 5.4pt}td.s{width:120.15pt;padding:0cm 5.4pt 0cm 5.4pt} /**/
RNS Number : 3512W
Silence Therapeutics PLC
16 April 2019


Silence Therapeutics Announces Board Change

April 16, 2019


LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces today that Dr. Andy Richards, CBE, is leaving his role as interim non-executive Chair and a Director of the Company with immediate effect. The Company's previously announced process to appoint a new Chair is ongoing.


Dr. David Horn Solomon, Chief Executive Officer, commented: "Andy Richards has served on the Board of Silence since 2016, first as a non-executive director and more recently as interim Chairman. During this time, Andy has been instrumental in a implementing a bold turnaround of Company strategy which has re-energised our drug-development programmes and led us to a point where we are now preparing to commence in-human trials with our lead RNAi candidate SLN124. I would like to thank Andy for his invaluable contribution to the Company and wish him well in his future endeavours."      





Silence Therapeutics plc

Dr David Horn Solomon, Chief Executive Officer

Dr Rob Quinn, Interim Chief Financial Officer

Tel:  +44 (0)20 3457 6900

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel/Oliver Jackson


Tel:  +44 (0)20 7418 8900

European IR

Consilium Strategic Communications

Mary-Jane Elliott/Angela Gray

[email protected]


Tel: +44 (0) 20 3709 5700


Westwicke Partners

Peter Vozzo

[email protected]

 Tel: +1 (443) 213-0505


About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/ 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Silence Therapeutics PLC

Price: 448

Market: AIM
Market Cap: £350.96 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Silence Therapeutics 'charging ahead with its key...

David Solomon, chief executive of Silence Therapeutics PLC (LON:SLN), updates on developments across their three key programmes - SLN 500, 124 and 360. Discussing the firm's current valuation, Solomon says ''there's a lot more steam in the engine''. ''I think that's what's exciting - we're...

3 weeks, 2 days ago